Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Revenue
ÂĄ100.4m
CAGR 3-Years
14%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Revenue
ÂĄ22.7B
CAGR 3-Years
22%
CAGR 5-Years
27%
CAGR 10-Years
52%
PeptiDream Inc
TSE:4587
Revenue
ÂĄ47.8B
CAGR 3-Years
45%
CAGR 5-Years
47%
CAGR 10-Years
51%
Takara Bio Inc
TSE:4974
Revenue
ÂĄ44.1B
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
6%
Pharma Foods International Co Ltd
TSE:2929
Revenue
ÂĄ60.6B
CAGR 3-Years
6%
CAGR 5-Years
41%
CAGR 10-Years
44%
C
Cuorips Inc
TSE:4894
Revenue
ÂĄ23.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Revenue?
Revenue
100.4m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Revenue amounts to 100.4m JPY.

What is Perseus Proteomics Inc's Revenue growth rate?
Revenue CAGR 5Y
-18%

Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Perseus Proteomics Inc have been 14% over the past three years , -18% over the past five years .

Back to Top